Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

[New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies].

Aguillón JC, Contreras J, Dotte A, Cruzat A, Catalán D, Salazar L, Molina MC, Guerrero J, López M, Soto L, Salazar-Onfray F, Cuchacovich M.

Rev Med Chil. 2003 Dec;131(12):1445-53. Review. Spanish.

PMID:
15022409
2.

Biological therapies for inflammatory bowel disease: research drives clinics.

Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A.

Mini Rev Med Chem. 2006 Jul;6(7):771-84. Review.

PMID:
16842127
3.

Anti-TNF therapy in Crohn's disease.

Ghosh S.

Novartis Found Symp. 2004;263:193-205; discussion 205-18. Review.

PMID:
15669643
4.
5.

Monoclonal antibodies in the treatment of systemic lupus erythematosus.

Robak E, Robak T.

Curr Drug Targets. 2009 Jan;10(1):26-37. Review.

PMID:
19149533
6.

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia.

Robak T.

Curr Cancer Drug Targets. 2008 Mar;8(2):156-71. Review.

PMID:
18336199
7.

Biological agents in rheumatoid arthritis: which ones could be used in combination?

Lorenz M, Kalden JR.

BioDrugs. 1998 Apr;9(4):303-24.

PMID:
18020567
8.

The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.

Toussirot E, Wendling D.

Expert Opin Pharmacother. 2007 Sep;8(13):2089-107. Review.

PMID:
17714062
9.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

10.

Emerging biologic drugs for the treatment of rheumatoid arthritis.

Puppo F, Murdaca G, Ghio M, Indiveri F.

Autoimmun Rev. 2005 Nov;4(8):537-41. Review.

PMID:
16214092
11.

[B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].

Yukawa N, Mimori T.

Clin Calcium. 2007 Apr;17(4):569-76. Review. Japanese.

PMID:
17404487
12.

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.

Lee J, Lee EN, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Lee KW, Kwon GY, Joh JW, Kim SJ.

Immunol Lett. 2005 Nov 15;101(2):210-6.

PMID:
16026855
13.

Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis.

di Comite G, Marinosci A, Di Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, Aiello P, Corti A, Sabbadini MG.

Ann N Y Acad Sci. 2006 Jun;1069:428-37.

PMID:
16855170
14.

Treatment of rheumatoid arthritis.

Gaffo A, Saag KG, Curtis JR.

Am J Health Syst Pharm. 2006 Dec 15;63(24):2451-65. Review.

PMID:
17158693
15.

Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects.

Leone G, Sica S, Voso MT, Rutella S, Pagano L.

Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):33-52. Review.

PMID:
16529548
16.

Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R.

Cancer Immunol Immunother. 2009 Aug;58(8):1195-206. doi: 10.1007/s00262-008-0632-0. Epub 2008 Dec 2.

PMID:
19048251
18.

Emerging biological therapies in rheumatoid arthritis.

Mariette X.

Joint Bone Spine. 2004 Nov;71(6):470-4. Review.

PMID:
15589425
19.

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.

Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN.

Arthritis Rheum. 2006 May;54(5):1429-34.

20.

Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.

Nishida M, Teshigawara K, Niwa O, Usuda S, Nakamura T, Ralph P, Newman R, Padlan EA.

Int J Oncol. 2008 Jun;32(6):1263-74.

PMID:
18497988

Supplemental Content

Support Center